Dashboard
Manage Tickers

VIRXViracta Therapeutics, Inc.

Nasdaq viracta.com


$ 0.23 $ 0.01 (2.99 %)    

Friday, 06-Sep-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 0.241
$ 0.24 x 300
$ 0.24 x 600
-- - --
$ 0.20 - $ 1.40
583,945
na
9.5M
$ 0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-07-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-14-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-16-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 02-24-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-10-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 03-07-2019 12-31-2018 10-K
24 11-05-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-09-2018 12-31-2017 10-K
28 11-02-2017 09-30-2017 10-Q
29 07-27-2017 06-30-2017 10-Q
30 05-08-2017 03-31-2017 10-Q
31 03-09-2017 12-31-2016 10-K
32 11-03-2016 09-30-2016 10-Q
33 07-29-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-14-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 07-30-2015 06-30-2015 10-Q
38 05-05-2015 03-31-2015 10-Q
39 03-12-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

leerink-partners-downgrades-viracta-therapeutics-to-market-perform-lowers-price-target-to-3
Leerink Partners Downgrades Viracta Therap...
08/16/2024 11:13:10

Leerink Partners analyst Andrew Berens downgrades Viracta Therapeutics (NASDAQ:VIRX) from Outperform to Market Perform and l...

rbc-capital-maintains-outperform-on-viracta-therapeutics-lowers-price-target-to-4
RBC Capital Maintains Outperform on Viract...
08/15/2024 14:55:58

RBC Capital analyst Gregory Renza maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target...

viracta-therapeutics-shares-are-trading-higher-after-the-company-reported-better-than-expected-q2-eps-results-also-the-company-announced-its-phase-2-naval-1-trial-results-and-will-begin-a-randomized-controlled-trial-rct
Viracta Therapeutics shares are trading hi...
08/14/2024 13:22:04

why-is-cancer-focused-penny-stock-viracta-therapeutics-trading-higher-on-wednesday
Why Is Cancer-Focused Penny Stock Viracta ...
08/14/2024 13:19:33

Viracta Therapeutics stock gains after Phase 2 NAVAL-1 trial results for relapsed or refractory EBV+ PTCL cohort. The company p...

viracta-therapeutics-q2-2024-gaap-eps-025-beats-037-estimate-cash-cash-equivalents-and-short-term-investments-of-approximately-30m-are-expected-to-be-sufficient-to-fund-operations-late-into-the-first-quarter-of-2025
Viracta Therapeutics Q2 2024 GAAP EPS $(0....
08/14/2024 11:11:52

viracta-therapeutics-reported-phase-2-naval-1-trial-results-from-stages-1-and-2-of-the-relapsed-or-refractory-epstein-barr-virus-positive-peripheral-t-cell-lymphoma-cohort
Viracta Therapeutics Reported Phase 2 NAVA...
08/14/2024 11:09:49

 Additionally, the Company received productive feedback from its meeting with the U.S. Food and Drug Administration (FDA), prov...

viracta-therapeutics-has-received-a-notice-of-allowance-for-its-us-patent-application-18240853-titled-hdac-inhibitor-solid-state-forms-for-the-treatment-of-cancer-immune-disorders-and-inflammation
Viracta Therapeutics Has Received A Notice...
08/09/2024 17:21:30

https://patentcenter.uspto.gov/applications/18240853/ifw/docs

why-digital-turbine-shares-are-trading-higher-by-over-20-here-are-20-stocks-moving-premarket
Why Digital Turbine Shares Are Trading Hig...
08/08/2024 10:02:17

on-july-22-2024-viracta-therapeutics-announced-workforce-reduction-affecting-about-23-to-be-completed-by-august-2024-the-company-anticipates-incurring-around-07m-in-severance-and-related-expenses-for-the-layoffs-8k
On July 22, 2024, Viracta Therapeutics, An...
07/29/2024 10:48:40

viracta-therapeutics-granted-us-patent-12012396-for-hdac-inhibitor-solid-state-forms-for-the-treatment-of-cancer-immune-disorders
Viracta Therapeutics Granted US Patent #12...
06/18/2024 19:05:19

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
06/11/2024 12:06:21

oppenheimer-maintains-outperform-on-viracta-therapeutics-lowers-price-target-to-11
Oppenheimer Maintains Outperform on Viract...
05/23/2024 12:22:32

Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target ...

viracta-therapeutics-appoints-michael-faerm-as-chief-financial-officer
Viracta Therapeutics Appoints Michael Faer...
05/14/2024 11:05:25

viracta-therapeutics-q1-2024-adj-eps-023-beats-035-estimate
Viracta Therapeutics Q1 2024 Adj EPS $(0.2...
05/09/2024 21:18:18

Viracta Therapeutics (NASDAQ:VIRX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of ...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
04/24/2024 12:06:37

why-travelers-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Travelers Shares Are Trading Lower By ...
04/17/2024 17:36:19

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
04/17/2024 16:31:40

oppenheimer-maintains-outperform-on-viracta-therapeutics-maintains-13-price-target
Oppenheimer Maintains Outperform on Viract...
04/17/2024 12:49:00

Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $13 price target.

hc-wainwright--co-reiterates-buy-on-viracta-therapeutics-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Vira...
04/16/2024 14:42:23

HC Wainwright & Co. analyst Robert Burns reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Buy and maintains $4 price...

why-is-small-cap-cancer-drug-developer-viracta-therapeutics-stock-trading-lower-on-monday
Why Is Small-Cap Cancer Drug Developer Vir...
04/15/2024 16:16:35

Nanatinostat combined with valganciclovir shows promising results in treating relapsed or refractory EBV+ peripheral T-cell lym...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION